- Home
- GITS vs GRDX Comparison
GITS vs GRDX Comparison
Compare GITS & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | GRDX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | South Korea | United Kingdom |
| Employees | 12 | 2 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 7.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GITS | GRDX |
|---|---|---|
| Price | $1.52 | $2.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.8K | ★ 98.6K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $1.87 |
| 52 Week High | $7.09 | $5.30 |
Technical Indicators
Market Signals| Indicator | GITS | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 55.35 |
| Support Level | $1.49 | $1.99 |
| Resistance Level | $2.44 | $2.73 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 31.33 | 51.91 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About GRDX GridAI Technologies Corp.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.